{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:07Z","timestamp":1790673907651,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T00:00:00Z","timestamp":1358899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Treatment of splenic marginal zone lymphoma (SMZL) patients is not standardized. Recent data suggest that rituximab is highly effective and could be considered as initial therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim.<\/jats:title>\n                  <jats:p>To assess the efficacy of rituximab monotherapy in a large series of patients with SMZL and compare these results with splenectomy results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>The studied population included 85 patients. Fifty-eight received rituximab at a dose of 375 mg\/m2 per week for 6 weeks as induction followed by maintenance at the same dose every 2 months for 1\u20132 years, whereas 27 patients were treated using splenectomy only.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The overall response rate to rituximab 2 months after the end of induction was 95% (complete response [CR], 45%; unconfirmed CR, 26%; partial response, 24%). The median times to hematologic and clinical response were 2 weeks and 3 weeks, respectively. Forty-three of 55 patients already completed the maintenance phase: 28 sustained their initial response, 14 improved their response, and one progressed. Eighty-five percent of splenectomized patients responded, and two were treated with rituximab as consolidation after splenectomy and achieved a CR. The 5-year overall and progression-free survival (PFS) rates for rituximab-treated and splenectomized patients were 92% and 77% (p = .09) and 73% and 58% (p = .06), respectively. Furthermore, maintenance therapy with rituximab resulted in a longer duration of response (at 5 years, PFS was 84% for patients receiving maintenance and 36% for patients without maintenance, p &amp;lt;.0001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>Rituximab is a very effective and well-tolerated therapy and may be substituted for splenectomy as the first-line treatment of choice for patients with SMZL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0251","type":"journal-article","created":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T10:59:39Z","timestamp":1359025179000},"page":"190-197","source":"Crossref","is-referenced-by-count":80,"title":["Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy"],"prefix":"10.1093","volume":"18","author":[{"given":"Christina","family":"Kalpadakis","sequence":"first","affiliation":[{"name":"a Department of Haematology, School of Medicine, University of Crete, Heraklion, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerassimos A.","family":"Pangalis","sequence":"additional","affiliation":[{"name":"a Department of Haematology, School of Medicine, University of Crete, Heraklion, Greece;"},{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"},{"name":"c Department of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Sachanas","sequence":"additional","affiliation":[{"name":"c Department of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora N.","family":"Kontopidou","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xanthi","family":"Yiakoumis","sequence":"additional","affiliation":[{"name":"c Department of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella I.","family":"Kokoris","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evagelia M.","family":"Dimitriadou","sequence":"additional","affiliation":[{"name":"c Department of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Dimopoulou","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moschogiannis","sequence":"additional","affiliation":[{"name":"c Department of Haematology, Athens Medical Center-Psychikon Branch, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Korkolopoulou","sequence":"additional","affiliation":[{"name":"d Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Kyrtsonis","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina P.","family":"Siakantaris","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Papadaki","sequence":"additional","affiliation":[{"name":"e Department of Pathology, Evangelismos Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Tsaftaridis","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Plata","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Papadaki","sequence":"additional","affiliation":[{"name":"a Department of Haematology, School of Medicine, University of Crete, Heraklion, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"b Department of Haematology, School of Medicine, National and Kapodistrian University of Athens, Athens Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,1,23]]},"reference":[{"key":"2021122308351795600_B1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122308351795600_B2","first-page":"185","volume-title":"World Health Organization. Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Isaacson","year":"2008"},{"key":"2021122308351795600_B3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"2021122308351795600_B4","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V83.6.1558.1558","article-title":"The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders","volume":"83","author":"Matutes","year":"1994","journal-title":"Blood"},{"key":"2021122308351795600_B5","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco","year":"2003","journal-title":"Blood"},{"key":"2021122308351795600_B6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.blre.2004.03.002","article-title":"Splenic marginal zone lymphoma","volume":"19","author":"Oscier","year":"2005","journal-title":"Blood Rev"},{"key":"2021122308351795600_B7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"2021122308351795600_B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: A distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"2021122308351795600_B9","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chac\u00f3n","year":"2002","journal-title":"Blood"},{"key":"2021122308351795600_B10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"2021122308351795600_B11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1046\/j.1365-2141.1996.d01-1711.x","article-title":"Splenic lymphoma with villous lymphocytes: Clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Frana\u0327is d'H\u00e9matologie Cellulaire (GFHC)","volume":"93","author":"Troussard","year":"1996","journal-title":"Br J Haematol"},{"key":"2021122308351795600_B12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1046\/j.1365-2141.2003.04165.x","article-title":"Prognostic features of splenic lymphoma with villous lymphocytes: A report on 129 patients","volume":"120","author":"Parry-Jones","year":"2003","journal-title":"Br J Haematol"},{"key":"2021122308351795600_B13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","article-title":"Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases","volume":"78","author":"Mulligan","year":"1991","journal-title":"Br J Haematol"},{"key":"2021122308351795600_B14","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: A prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"2021122308351795600_B15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood.V99.4.1299","article-title":"Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course","volume":"99","author":"Algara","year":"2002","journal-title":"Blood"},{"key":"2021122308351795600_B16","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood.V97.11.3552","article-title":"p53 abnormalities in splenic lymphoma with villous lymphocytes","volume":"97","author":"Gruszka-Westwood","year":"2001","journal-title":"Blood"},{"key":"2021122308351795600_B17","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to large B-cell lymphoma in splenic marginal zone lymphoma: A description of a series of 12 cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"2021122308351795600_B18","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2004-10-3898","article-title":"Splenic marginal zone lymphoma: Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis","volume":"106","author":"Ruiz-Ballesteros","year":"2005","journal-title":"Blood"},{"key":"2021122308351795600_B19","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"key":"2021122308351795600_B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11864-007-0026-0","article-title":"Splenic marginal zone lymphoma with and without villous lymphocytes","volume":"8","author":"Matutes","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"2021122308351795600_B21","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.20596","article-title":"Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients","volume":"101","author":"Iannitto","year":"2004","journal-title":"Cancer"},{"key":"2021122308351795600_B22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefr\u00e8re","year":"2000","journal-title":"Leukemia"},{"key":"2021122308351795600_B23","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"2021122308351795600_B24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"2021122308351795600_B25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"key":"2021122308351795600_B26","article-title":"Rituximab monotherapy is the treatment of choice for splenic marginal zone lymphoma (SMZL)","volume":"19","author":"Kalpadakis","year":"2008","journal-title":"Ann Oncol"},{"key":"2021122308351795600_B27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V83.5.1165.1165","article-title":"Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has \u201chigh-risk\u201d disease?","volume":"83","author":"Shipp","year":"1994","journal-title":"Blood"},{"key":"2021122308351795600_B28","first-page":"1811","article-title":"Mutation analysis of IgVH genes in splenic marginal zone lymphomas: Correlation with clinical characteristics and outcome","volume":"29","author":"Kalpadakis","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122308351795600_B29","first-page":"148","article-title":"Splenic lymphoma with circulating villous lymphocytes\/splenic marginal-zone lymphoma","volume":"36","author":"Catovsky","year":"1999","journal-title":"Semin Hematol"},{"key":"2021122308351795600_B30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: Splenectomy versus rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin Hematol"},{"key":"2021122308351795600_B31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3816\/CLM.2006.n.033","article-title":"Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia","volume":"6","author":"Fabbri","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2021122308351795600_B32","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/1042819031000123555","article-title":"Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase","volume":"44","author":"Paydas","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"2021122308351795600_B33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122308351795600_B34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3109\/10428194.2010.534518","article-title":"Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: A highly effective regimen","volume":"52","author":"Sachanas","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021122308351795600_B35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"2021122308351795600_B36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1097-0142(20010115)91:2<294::AID-CNCR1001>3.0.CO;2-W","article-title":"Splenectomy influences marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes","volume":"91","author":"Franco","year":"2001","journal-title":"Cancer"},{"key":"2021122308351795600_B37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2141.1997.3523168.x","article-title":"Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes","volume":"99","author":"Bolam","year":"1997","journal-title":"Br J Haematol"},{"key":"2021122308351795600_B38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","article-title":"Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes","volume":"75","author":"Iannitto","year":"2005","journal-title":"Eur J Haematol"},{"key":"2021122308351795600_B39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428190009054887","article-title":"Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes","volume":"40","author":"Lefr\u00e8re","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"2021122308351795600_B40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.717","article-title":"Low dose 2-CdA schedule activity in splenic marginal zone lymphomas","volume":"21","author":"Riccioni","year":"2003","journal-title":"Hematol Oncol"},{"key":"2021122308351795600_B41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/annonc\/mdp395","article-title":"Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)","volume":"21","author":"Cervetti","year":"2010","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0251","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/2\/190\/41856827\/oncolo_18_2_190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/2\/190\/41856827\/oncolo_18_2_190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:49:40Z","timestamp":1640306980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/2\/190\/6398750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,23]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,1,23]]},"published-print":{"date-parts":[[2013,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0251","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,2,1]]},"published":{"date-parts":[[2013,1,23]]}}}